Jaime Rosenberg

September 28, 2022

This new series of cases suggests that technology can help nurses remotely identify relevant health events that could be indicative of exacerbations or changes in their condition.

September 21, 2022

With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.

September 18, 2022

The findings, produced over a 4-year period, indicate the protein sulfatase-2 (Sulf-2) may be a therapeutic target in rheumatoid arthritis (RA).

September 16, 2022

This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response

September 16, 2022

The study analyzed 20 clinical prediction models (CPMs) for rheumatoid arthritis (RA), all of which were deemed to have a high risk of bias, leading the researchers to urge against their use to guide decision-making without addressing their limitations.

September 13, 2022

The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).

September 13, 2022

Data from a literature review of 41 studies were analyzed and subsequently leveraged to create a survey among physicians on the use of 4 targeted therapies in systemic sclerosis-interstitial lung disease (SSc-ILD).

September 12, 2022

The review included data from 17 studies of over 400 patients using continuous glucose monitors (CGM).

September 09, 2022

Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.

September 07, 2022

The trial followed patients with type 1 diabetes (T1D) for 6 months, evaluating outcomes in patients struggling to achieve glucose targets with the conventional treatment.